RE:RE:Question That was a question in the KOL event and Marsolais emphatically stated their peptide does not cross BBB and Beliveau nodded along with him.
My recollection from reading some of the original Katana and Angiochem material was that the labs initial focus was finding a way to cross the BBB and designing drugs for that purpose. That is what Angiochem is doing. same team also discovered this peptide that latched to sort1. It didn't work for brain tumors, but they saw it could work for other solid tumors with high Sort1 and spun the tech out as Katana. When they were pitching it around the whole science behind sort1 was still very early. You can see from the dates of Beliveau articles on the website that it was truly groundbreaking science UQAM did. They beat the Gothenburg guys by years.I'm sure one of the reasons Katana took a year or more to find a partner was that it was so early and very little clinical work had been done around that idea. It fit well with an equally smallish company able to put $10mil down to see if it could advance in the lab. Kudos to THTX mgmt for taking that risk.
qwerty22 wrote:
Sortilin is best known as a brain protein, it's expressed on the surface of neurons. I would think one of the first things you look at is does it cross the BBB. If Katana/thtx haven't ticked this off the to do list early in the process then we are invested in fools. Could they have not done this? Are they all fools?
SABBOBCAT wrote: Wasn't Katana working on peptides to cross the blood bran barrier before selling the platform to TH? Is there any risk that the PDC would cross the BBB and have into tended side effects?